uniQure submits biologics license application for ifezuntirgene inilparvovec in Huntington’s
uniQure (QURE) announced submission of a Biologics License Application for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.